MX2022001115A - Inhibidores de proteina quinasa de pirazolo-piridina sustituida con heteroarilo para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocito. - Google Patents

Inhibidores de proteina quinasa de pirazolo-piridina sustituida con heteroarilo para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocito.

Info

Publication number
MX2022001115A
MX2022001115A MX2022001115A MX2022001115A MX2022001115A MX 2022001115 A MX2022001115 A MX 2022001115A MX 2022001115 A MX2022001115 A MX 2022001115A MX 2022001115 A MX2022001115 A MX 2022001115A MX 2022001115 A MX2022001115 A MX 2022001115A
Authority
MX
Mexico
Prior art keywords
reducing
pyridine
protein kinase
heteroaryl
liver regeneration
Prior art date
Application number
MX2022001115A
Other languages
English (en)
Inventor
Wolfgang Albrecht
Stefan Laufer
Roland Selig
Bent Pfaffenrot
Original Assignee
Heparegenix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heparegenix Gmbh filed Critical Heparegenix Gmbh
Publication of MX2022001115A publication Critical patent/MX2022001115A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos de pirazolo-piridina los cuales inhiben la proteína quinasa quinasa activada por mitógeno 4 (MKK4) y en particular, inhiben de manera selectiva a MKK4 sobre las proteína quinasas JNK1 y MKK7. Los compuestos son útiles para promover la regeneración hepática o reducir o prevenir la muerte de hepatocito. Éstos son útiles también para tratar osteoartritis o artritis reumatoide, o enfermedades relacionadas con el SNC.
MX2022001115A 2019-07-29 2020-07-27 Inhibidores de proteina quinasa de pirazolo-piridina sustituida con heteroarilo para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocito. MX2022001115A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19188876 2019-07-29
EP20172253 2020-04-30
PCT/EP2020/071090 WO2021018820A1 (en) 2019-07-29 2020-07-27 Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Publications (1)

Publication Number Publication Date
MX2022001115A true MX2022001115A (es) 2022-05-03

Family

ID=71894788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001115A MX2022001115A (es) 2019-07-29 2020-07-27 Inhibidores de proteina quinasa de pirazolo-piridina sustituida con heteroarilo para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocito.

Country Status (11)

Country Link
US (1) US20220340561A1 (es)
EP (1) EP4003991A1 (es)
JP (1) JP2022544074A (es)
KR (1) KR20220046584A (es)
CN (1) CN114269745A (es)
AU (1) AU2020320001A1 (es)
BR (1) BR112022001488A2 (es)
CA (1) CA3148780A1 (es)
IL (1) IL290190A (es)
MX (1) MX2022001115A (es)
WO (1) WO2021018820A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51889A (fr) 2018-01-31 2021-05-05 Heparegenix Gmbh Inhibiteurs de protéine kinase mkk4 pour favoriser la régénération hépatique ou pour réduire ou prévenir la mort des hépatocytes
US11731968B2 (en) 2018-06-21 2023-08-22 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
SG11202012732UA (en) 2018-07-16 2021-02-25 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2023194443A1 (en) 2022-04-06 2023-10-12 Heparegenix Gmbh Pharmaceutical composition for the treatment of colon and lung cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04004019A (es) * 2001-10-31 2004-07-08 Bayer Healthcare Ag Derivados de pirimido?4,5-b?indol.
AU2003300522A1 (en) * 2002-12-27 2004-07-22 Bayer Healthcare Ag 4-phenyl-pyrimido (4,5-b) indole derivatives
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
PT2427415T (pt) 2009-05-08 2019-05-31 Basf As Ácidos gordos polinsaturados para o tratamento de doenças relacionadas com as áreas cardiovascular, metabólica e de doença inflamatória
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2508607A1 (en) * 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
MX2015015966A (es) 2013-05-30 2016-04-13 Plexxikon Inc Compuestos para la modulacion de cinasas e indicaciones para los mismos.
CA2972919A1 (en) 2015-01-09 2016-07-14 Gilead Apollo, Llc Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
US10717734B2 (en) 2016-02-12 2020-07-21 Pharmaxis Ltd. Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
MA51889A (fr) * 2018-01-31 2021-05-05 Heparegenix Gmbh Inhibiteurs de protéine kinase mkk4 pour favoriser la régénération hépatique ou pour réduire ou prévenir la mort des hépatocytes
RU2678455C1 (ru) * 2018-06-01 2019-01-29 Сергей Викторович Леонов Кристаллическая форма n-(3-(5-(4-хлорофенил)-1н-пиразоло[3,4-в]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамида, активный компонент, фармацевтическая композиция и лекарственное средство

Also Published As

Publication number Publication date
IL290190A (en) 2022-03-01
BR112022001488A2 (pt) 2022-04-19
WO2021018820A1 (en) 2021-02-04
EP4003991A1 (en) 2022-06-01
US20220340561A1 (en) 2022-10-27
JP2022544074A (ja) 2022-10-17
AU2020320001A1 (en) 2022-03-10
CA3148780A1 (en) 2021-02-04
CN114269745A (zh) 2022-04-01
KR20220046584A (ko) 2022-04-14

Similar Documents

Publication Publication Date Title
MX2020007954A (es) Inhibidores de la proteina cinasa cinasa 4 activada por mitogeno (mkk4) para promover la regeneracion del higado o reducir o prevenir la muerte de los hepatocitos.
MX2022001115A (es) Inhibidores de proteina quinasa de pirazolo-piridina sustituida con heteroarilo para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocito.
MX2019008458A (es) Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos.
MX2020014102A (es) Inhibidores de proteina quinasa para promover la regeneracion del higado o reducir o prevenir la muerte de hepatocito.
MX2022002938A (es) Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta).
MX2018001395A (es) Derivados de pirazol pirimidina y sus usos.
PH12018501268A1 (en) Compounds useful as kinase inhibitors
JOP20220242A1 (ar) أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3
MX2021001550A (es) Inhibidores de transglutaminasa 2 (tg2).
PH12017502203A1 (en) Tyrosine kinase inhibitors
BR112017022349A2 (pt) ?composto, composição, método, e, método para inibir uma proteína irak?
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
EA201100688A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
MX2010005768A (es) Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral.
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
EA201070611A1 (ru) Ингибиторы человеческой фосфатидилинозитол-3-киназы дельта
MY185579A (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
WO2018195110A8 (en) Regulation of ran translation by pkr and eif2a-p pathways
MX2008001538A (es) Aril piridinas y metodos para su uso.
MY179042A (en) Kinase inhibitors with improved cyp safety profile
PH12020550195A1 (en) Use of p38 inhibitors to reduce expression of dux4
MX2018009189A (es) Compuestos de anillo de siete miembros de pirimidina.
MX2009010205A (es) Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.
MY201291A (en) Aminothiazole compounds as protein kinase inhibitors
MX2019009943A (es) Proteínas que se unen a gd2, nkg2d y cd16.